Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 StudiesGlobeNewsWire • 10/22/19
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology WeekGlobeNewsWire • 10/21/19
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular DisordersGlobeNewsWire • 10/02/19
Biogen Stock Flailed On Alzheimer's Flop — Is This Biotech Stock A Buy Now?Investors Business Daily • 10/01/19
Biogen names Alfred Sandrock EVP of R&D, replacing Michael Ehlers who is leaving companyMarket Watch • 10/01/19
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and BreastfeedingGlobeNewsWire • 09/23/19
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of PatientsGlobeNewsWire • 09/18/19
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World IndexGlobeNewsWire • 09/17/19
Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares PopInvestors Business Daily • 09/13/19
Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatmentMarket Watch • 09/13/19
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment SpectrumGlobeNewsWire • 09/12/19
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 YearsGlobeNewsWire • 09/11/19